Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Deferred Revenue (2016 - 2025)

Ptc Therapeutics has reported Current Deferred Revenue over the past 14 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $2.0 million for Q4 2025, down 62.94% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 62.94% YoY), and the annual figure for FY2025 was $2.0 million, down 62.94%.
  • Current Deferred Revenue for Q4 2025 was $2.0 million at Ptc Therapeutics, up from $1.7 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PTCT hit a ceiling of $12.8 million in Q1 2025 and a floor of $214000.0 in Q1 2023.
  • Median Current Deferred Revenue over the past 5 years was $1.8 million (2021), compared with a mean of $3.7 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 78.15% in 2021 and later skyrocketed 587.27% in 2024.
  • Ptc Therapeutics' Current Deferred Revenue stood at $1.9 million in 2021, then decreased by 28.4% to $1.4 million in 2022, then crashed by 40.71% to $801000.0 in 2023, then skyrocketed by 587.27% to $5.5 million in 2024, then plummeted by 62.94% to $2.0 million in 2025.
  • The last three reported values for Current Deferred Revenue were $2.0 million (Q4 2025), $1.7 million (Q3 2025), and $9.8 million (Q2 2025) per Business Quant data.